Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity

The Daily Chemotherapy Toxicity self-Assessment Questionnaire

Roma Maguire, Grigorios Kotronoulas, Peter T. Donnan, Catherine Paterson, Lisa McCann, John Connaghan, David G.G. Di Domenico, Nora Kearney

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n = 15) and cognitive debriefing with patients with cancer (n = 7) were used to establish content validity. Feasibility/acceptability, applicability (self-report vs. interview-like administration), internal consistency (KR-20) and test–retest reliability (at 1-hr intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended “any other symptom” item. Feasibility and acceptability were demonstrated through the absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20 = 0.56), but very good test–retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.

Original languageEnglish
Article numbere12890
Pages (from-to)1-10
Number of pages10
JournalEuropean Journal of Cancer Care
Volume27
Issue number6
DOIs
Publication statusPublished - 1 Nov 2018
Externally publishedYes

Fingerprint

Drug Therapy
Surveys and Questionnaires
Self-Assessment
Quality of Health Care
Self Report
Colorectal Neoplasms
Interviews
Breast Neoplasms
Neoplasms

Cite this

Maguire, Roma ; Kotronoulas, Grigorios ; Donnan, Peter T. ; Paterson, Catherine ; McCann, Lisa ; Connaghan, John ; Di Domenico, David G.G. ; Kearney, Nora. / Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity : The Daily Chemotherapy Toxicity self-Assessment Questionnaire. In: European Journal of Cancer Care. 2018 ; Vol. 27, No. 6. pp. 1-10.
@article{91054a4c885a4e2f8bd62400dec378f1,
title = "Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire",
abstract = "Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n = 15) and cognitive debriefing with patients with cancer (n = 7) were used to establish content validity. Feasibility/acceptability, applicability (self-report vs. interview-like administration), internal consistency (KR-20) and test–retest reliability (at 1-hr intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended “any other symptom” item. Feasibility and acceptability were demonstrated through the absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20 = 0.56), but very good test–retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.",
keywords = "cancer, chemotherapy toxicity, Daily Chemotherapy Toxicity self-Assessment Questionnaire, patient-reported outcomes, reliability, validity",
author = "Roma Maguire and Grigorios Kotronoulas and Donnan, {Peter T.} and Catherine Paterson and Lisa McCann and John Connaghan and {Di Domenico}, {David G.G.} and Nora Kearney",
year = "2018",
month = "11",
day = "1",
doi = "10.1111/ecc.12890",
language = "English",
volume = "27",
pages = "1--10",
journal = "European Journal of Cancer Care (Online)",
issn = "0961-5423",
publisher = "Wiley-Blackwell",
number = "6",

}

Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity : The Daily Chemotherapy Toxicity self-Assessment Questionnaire. / Maguire, Roma; Kotronoulas, Grigorios; Donnan, Peter T.; Paterson, Catherine; McCann, Lisa; Connaghan, John; Di Domenico, David G.G.; Kearney, Nora.

In: European Journal of Cancer Care, Vol. 27, No. 6, e12890, 01.11.2018, p. 1-10.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity

T2 - The Daily Chemotherapy Toxicity self-Assessment Questionnaire

AU - Maguire, Roma

AU - Kotronoulas, Grigorios

AU - Donnan, Peter T.

AU - Paterson, Catherine

AU - McCann, Lisa

AU - Connaghan, John

AU - Di Domenico, David G.G.

AU - Kearney, Nora

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n = 15) and cognitive debriefing with patients with cancer (n = 7) were used to establish content validity. Feasibility/acceptability, applicability (self-report vs. interview-like administration), internal consistency (KR-20) and test–retest reliability (at 1-hr intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended “any other symptom” item. Feasibility and acceptability were demonstrated through the absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20 = 0.56), but very good test–retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.

AB - Close monitoring of chemotherapy toxicity can be instrumental in ensuring prompt symptom management and quality care. Our aim was to develop a brief clinical tool to enable daily assessment of chemotherapy toxicity and investigate/establish its content validity, feasibility/applicability, internal consistency and stability. Development of the Daily Chemotherapy Toxicity self-Assessment Questionnaire (DCTAQ) was based on an initial item pool created from two scoping reviews. Expert panel review (n = 15) and cognitive debriefing with patients with cancer (n = 7) were used to establish content validity. Feasibility/acceptability, applicability (self-report vs. interview-like administration), internal consistency (KR-20) and test–retest reliability (at 1-hr intervals) of the DCTAQ were field-tested with 82 patients with breast or colorectal cancer receiving active chemotherapy at eight hospitals. Initial development/content validity stages enabled item revisions and re-wording that led to a final, 11-item DCTAQ version with 10 core symptom items plus one open-ended “any other symptom” item. Feasibility and acceptability were demonstrated through the absence of participant withdrawals, absence of missing data and no complaints about tool length. The DCTAQ was found to have modest internal consistency (KR-20 = 0.56), but very good test–retest reliability. The DCTAQ is a brief clinical tool that allows for rapid and accurate daily assessments of chemotherapy toxicity in clinical practice.

KW - cancer

KW - chemotherapy toxicity

KW - Daily Chemotherapy Toxicity self-Assessment Questionnaire

KW - patient-reported outcomes

KW - reliability

KW - validity

UR - http://www.scopus.com/inward/record.url?scp=85050654013&partnerID=8YFLogxK

U2 - 10.1111/ecc.12890

DO - 10.1111/ecc.12890

M3 - Article

VL - 27

SP - 1

EP - 10

JO - European Journal of Cancer Care (Online)

JF - European Journal of Cancer Care (Online)

SN - 0961-5423

IS - 6

M1 - e12890

ER -